CureVac NV
CVAC5.430USD
+0.020+0.37%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.22BMarktkapitalisierung
6.77KGV TTM
mehr Informationen über CureVac NV Unternehmen
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Unternehmensinformationen
BörsenkürzelCVAC
Name des UnternehmensCureVac NV
IPO-datumAug 14, 2020
CEODr. Alexander Zehnder, M.D.
Anzahl der mitarbeiter825
WertpapierartOrdinary Share
GeschäftsjahresendeAug 14
AddresseFriedrich-Miescher-Str. 15
StadtTUEBINGEN
BörseNASDAQ Global Market Consolidated
LandGermany
Postleitzahl72076
Telefon49707198830
Websitehttps://www.curevac.com/
BörsenkürzelCVAC
IPO-datumAug 14, 2020
CEODr. Alexander Zehnder, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Umsatzaufteilung
Währung: EURAktualisiert: Sun, Jul 6
Währung: EURAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionEUR
Name
Umsatz
Anteil
Switzerland
586.00K
65.62%
Belgium (Country)
306.00K
34.27%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 23
Aktualisiert: Wed, Jul 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Other
42.80%
Aktionäre
Aktionäre
Anteil
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Other
42.80%
Aktionärstypen
Aktionäre
Anteil
Corporation
36.61%
Government Agency
13.27%
Holding Company
7.37%
Investment Advisor
1.31%
Hedge Fund
0.93%
Investment Advisor/Hedge Fund
0.89%
Foundation
0.70%
Bank and Trust
0.41%
Research Firm
0.30%
Other
38.23%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
248
139.54M
61.97%
-14.77M
2025Q1
256
140.77M
62.52%
-15.67M
2024Q4
257
142.22M
63.40%
-15.15M
2024Q3
264
144.04M
64.21%
-15.50M
2024Q2
284
147.06M
65.56%
-13.88M
2024Q1
303
150.44M
67.06%
-10.89M
2023Q4
317
154.94M
69.64%
-16.33M
2023Q3
339
166.99M
75.03%
-5.02M
2023Q2
359
168.77M
75.83%
-4.22M
2023Q1
383
169.76M
76.27%
+21.54M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
DH Capital GmbH & Co. KG
70.18M
31.17%
--
--
Jun 12, 2025
KfW
29.87M
13.27%
--
--
Mar 15, 2025
Glaxo Group, Ltd.
16.59M
7.37%
--
--
Mar 15, 2025
DH-LT-Investments GmbH
8.75M
3.89%
--
--
Jun 12, 2025
Zweite DH Verwaltungs GmbH
3.40M
1.51%
--
--
Jun 12, 2025
Millennium Management LLC
1.82M
0.81%
+169.95K
+10.32%
Mar 31, 2025
Bill & Melinda Gates Foundation
1.57M
0.7%
-28.77K
-1.80%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
598.13K
0.27%
-7.56K
-1.25%
Mar 31, 2025
UBS Switzerland AG
497.53K
0.22%
+424.90K
+585.03%
Mar 31, 2025
BlackRock Advisors (UK) Limited
347.00K
0.15%
+3.49K
+1.02%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Global X Genomics & Biotechnology ETF
0.65%
WisdomTree BioRevolution Fund
0.56%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.05%
iShares MSCI Europe Small-Cap ETF
0.04%
iShares MSCI EAFE Small-Cap ETF
0.02%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.87%
Global X Genomics & Biotechnology ETF
Anteil0.65%
WisdomTree BioRevolution Fund
Anteil0.56%
ProShares Ultra Nasdaq Biotechnology
Anteil0.14%
Invesco Nasdaq Biotechnology ETF
Anteil0.14%
iShares Biotechnology ETF
Anteil0.05%
iShares MSCI Europe Small-Cap ETF
Anteil0.04%
iShares MSCI EAFE Small-Cap ETF
Anteil0.02%
Xtrackers MSCI Eurozone Hedged Eqty ETF
Anteil0.01%
Fidelity Nasdaq Composite Index ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
